Literature DB >> 18042774

Anticoagulation for prosthetic heart valves in pregnancy. Is there an answer?

Amir J Khamooshi1, Fahimeh Kashfi, Saeed Hoseini, Mohammad B Tabatabaei, Hossein Javadpour, Fereydoon Noohi.   

Abstract

The aim of this retrospective study was to compare the different anticoagulation regimens used in pregnant women with prosthetic heart valves. We reviewed 196 pregnancies in 110 women from 1974 to 2000. The patients were divided into two groups: group 1 (142 pregnancies) had warfarin throughout pregnancy; and in group 2 (54 pregnancies), warfarin was replaced by subcutaneous heparin during the first trimester and last two weeks of pregnancy. There were no maternal complications in 129 pregnancies in group 1 and 44 in group 2. There were significantly fewer normal births in group 1 (56; 39.4%) compared to group 2 (39; 72.2%). Group 1 had a significantly higher rate of spontaneous abortion (46.5% vs 14.8%), but group 2 had a higher rate of valve thrombosis. In group 1, women with a warfarin requirement < 5 mg had a lower rate of spontaneous abortion. Warfarin is an effective anticoagulant in pregnant women with mechanical valves but it results in significant fetal loss when the dose is > 5 mg. Heparin is a less effective anticoagulant resulting in more maternal complications, but it is more protective of the fetus.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18042774     DOI: 10.1177/021849230701500609

Source DB:  PubMed          Journal:  Asian Cardiovasc Thorac Ann        ISSN: 0218-4923


  12 in total

Review 1.  Mechanical Prosthetic Valves and Pregnancy: A therapeutic dilemma of anticoagulation.

Authors:  Prashanth Panduranga; Mohammed El-Deeb; Chitra Jha
Journal:  Sultan Qaboos Univ Med J       Date:  2014-10-14

2.  VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Shannon M Bates; Ian A Greer; Saskia Middeldorp; David L Veenstra; Anne-Marie Prabulos; Per Olav Vandvik
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 3.  Is there a suitable method of anticoagulation in pregnant patients with mechanical prosthetic heart valves?

Authors:  Humza T Malik; Amir H Sepehripour; Alex R Shipolini; David J McCormack
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-05-25

Review 4.  Atrial fibrillation during pregnancy: a 9-month period with limited options.

Authors:  Konstantinos Iliodromitis; Jacek Kociszewski; Harilaos Bogossian
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2021-04-06

Review 5.  Use of medication for cardiovascular disease during pregnancy.

Authors:  Petronella G Pieper
Journal:  Nat Rev Cardiol       Date:  2015-12       Impact factor: 32.419

6.  Antithrombotic therapy in patients with prosthetic heart valves.

Authors:  Ha Mohamed
Journal:  Libyan J Med       Date:  2009-03-01       Impact factor: 1.657

7.  An audit of pregnant women with prosthetic heart valves at a tertiary hospital in South Africa: a five-year experience.

Authors:  B Mazibuko; H Ramnarain; J Moodley
Journal:  Cardiovasc J Afr       Date:  2012-05       Impact factor: 1.167

8.  Pregnancy outcome after mechanical mitral valve replacement: a prospective study.

Authors:  Niloufar Samiei; Fahimeh Kashfi; Amirjamshid Khamoushi; Saeid Hosseini; Alireza Alizadeh Ghavidel; Robabeh Taheripanah; Yalda Mirmesdagh
Journal:  J Tehran Heart Cent       Date:  2012-08-31

9.  Anti-coagulation during pregnancy in women with mechanical heart valves: a prospective study.

Authors:  Amir Jamshid Khamoushi; Fahimeh Kashfi; Saeid Hosseini; Ali Reza Alizadeh Ghavidel; Niloufar Samiei; Mehdi Haddadzadeh
Journal:  Int J Fertil Steril       Date:  2011-03-21

10.  Continued use of Warfarin in lower dose has safe maternal and neonatal outcomes in pregnant women with Prosthetic Heart Valves.

Authors:  Shafaq Nadeem; Shabaz Ahmad Khilji; Faisal Ali; Anjum Jalal
Journal:  Pak J Med Sci       Date:  2021 Jul-Aug       Impact factor: 1.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.